ArriVent BioPharma (AVBP) Non-Current Assets (2023 - 2026)
ArriVent BioPharma (AVBP) posted Non-Current Assets of $595000.0 for Q1 2026, up 118.75% sequentially from $272000.0 in Q4 2025, and down 98.0% YoY from $29.7 million in Q1 2025.
ArriVent BioPharma (AVBP) Non-Current Assets (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Non-Current Assets for 4 years, with the latest figure at $595000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 98.0% year-over-year to $595000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.6 million (down 67.37% YoY) and the FY2025 annual result came in at $272000.0, down 99.43% from the prior year.
- Non-Current Assets rose to $595000.0 in Q1 2026 per AVBP's latest filing, from $272000.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $48.0 million in Q4 2024 and troughed at $272000.0 in Q4 2025.
- A 4-year average of $10.7 million and a median of $1.9 million in 2023 frame the typical range for Non-Current Assets.
- The widest YoY moves for Non-Current Assets: up 8198.88% in 2025, down 99.43% in 2025.
- Over 4 years, Non-Current Assets stood at $3.1 million in 2023, then soared by 1432.36% to $48.0 million in 2024, then slumped by 99.43% to $272000.0 in 2025, then jumped by 118.75% to $595000.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $595000.0, $272000.0, and $5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | 545,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 545,000.00 |
| Mar 31, 2026 | 595,000.00 |
| Dec 31, 2025 | 272,000.00 |
| Sep 30, 2025 | 5.34 Mn |
| Jun 30, 2025 | 19.36 Mn |
| Mar 31, 2025 | 29.71 Mn |
| Dec 31, 2024 | 47.96 Mn |
| Sep 30, 2024 | 313,000.00 |
| Jun 30, 2024 | 344,000.00 |
| Mar 31, 2024 | 358,000.00 |
| Dec 31, 2023 | 3.13 Mn |